Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep 12:3:170.
doi: 10.3389/fgene.2012.00170. eCollection 2012.

The non-coding oncogene: a case of missing DNA evidence?

Affiliations
Review

The non-coding oncogene: a case of missing DNA evidence?

Puja Shahrouki et al. Front Genet. .

Abstract

The evidence that links classical protein-coding proto-oncogenes and tumor suppressors, such as MYC, RAS, P53, and RB, to carcinogenesis is indisputable. Multiple lines of proof show how random somatic genomic alteration of such genes (e.g., mutation, deletion, or amplification), followed by selection and clonal expansion, forms the main molecular basis of tumor development. Many important cancer genes were discovered using low-throughput approaches in the pre-genomic era, and this knowledge is today solidified and expanded upon by modern genome-scale methodologies. In several recent studies, non-coding RNAs (ncRNAs), such as microRNAs and long ncRNAs (lncRNAs), have been shown to contribute to tumor development. However, in comparison with coding cancer genes, the genomic (DNA-level) evidence is sparse for ncRNAs. The coding proto-oncogenes and tumor suppressors that we know of today are major molecular hubs in both normal and malignant cells. The search for ncRNAs with tumor driver or suppressor roles therefore holds the additional promise of pinpointing important, biologically active, ncRNAs in a vast and largely uncharacterized non-coding transcriptome. Here, we assess the available DNA-level data that links non-coding genes to tumor development. We further consider historical, methodological, and biological aspects, and discuss future prospects of ncRNAs in cancer.

Keywords: T-UCR; cancer; lincRNA; lncRNA; microRNA; mutation; non-coding RNA; somatic alteration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative abundances of major human gene categories. The figure is based on the GENCODE (Harrow et al., 2006) annotation (version 11), and numbers refer to gene counts rather than transcripts. Note that additional transcribed loci have been described in other high-throughput gene annotation efforts. Coding genes and lncRNAs were defined as described previously (Jeggari et al., 2012). Pseudogenes here refer to the GENCODE “pseudogene” and “polymorphic pseudogene” categories, and do not include ncRNA pseudogenes. “Misc. RNA” mainly comprises Y RNAs and 7SK RNAs.

Similar articles

Cited by

References

    1. Arvey A., Larsson E., Sander C., Leslie C. S., Marks D. S. (2010). Target mRNA abundance dilutes microRNA and siRNA activity. Mol. Syst. Biol. 6, 363.10.1038/msb.2010.24 - DOI - PMC - PubMed
    1. Augello C., Vaira V., Caruso L., Destro A., Maggioni M., Park Y. N., Montorsi M., Santambrogio R., Roncalli M., Bosari S. (2012). MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 32, 772–78210.1111/j.1478-3231.2012.02795.x - DOI - PubMed
    1. Bartel D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215–23310.1016/j.cell.2009.01.002 - DOI - PMC - PubMed
    1. Bejerano G., Pheasant M., Makunin I., Stephen S., Kent W. J., Mattick J. S., Haussler D. (2004). Ultraconserved elements in the human genome. Science 304, 1321–132510.1126/science.1098119 - DOI - PubMed
    1. Bernard D., Prasanth K. V., Tripathi V., Colasse S., Nakamura T., Xuan Z., Zhang M. Q., Sedel F., Jourdren L., Coulpier F., Triller A., Spector D. L., Bessis A. (2010). A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J. 29, 3082–309310.1038/emboj.2010.199 - DOI - PMC - PubMed